Targeted Protein Degradation through Recruitment of the CUL4A Complex Adaptor Protein DDB1.

AR BRD4 CUL4A DDB1 activity-based protein profiling androgen receptor chemoproteomics covalent targeted protein degradation

Journal

bioRxiv : the preprint server for biology
Titre abrégé: bioRxiv
Pays: United States
ID NLM: 101680187

Informations de publication

Date de publication:
12 Aug 2023
Historique:
pubmed: 24 8 2023
medline: 24 8 2023
entrez: 24 8 2023
Statut: epublish

Résumé

Targeted protein degradation has arisen as a powerful therapeutic modality for eliminating proteins. Thus far, most heterobifunctional Proteolysis Targeting Chimeras (PROTACs) have utilized recruiters against substrate receptors of Cullin RING E3 ubiquitin ligases, such as cereblon and VHL. However, previous studies have surprisingly uncovered molecular glue degraders that exploit a CUL4A adaptor protein DDB1 to degrade neosubstrate proteins. Here, we sought to investigate whether DDB1 recruiters can be discovered that can be exploited for PROTAC applications. We utilized activity-based protein profiling and cysteine chemoproteomic screening to identify a covalent recruiter that targets C173 on DDB1 and exploited this recruiter to develop PROTACs against BRD4 and androgen receptor (AR). We demonstrated that the BRD4 PROTAC results in selective degradation of the short BRD4 isoform over the long isoform in a proteasome, NEDDylation, and DDB1-dependent manner. We also demonstrated degradation of AR with the AR PROTAC in prostate cancer cells. Our study demonstrated that covalent chemoproteomic approaches can be used to discover recruiters against Cullin RING adapter proteins and that these recruiters can be used for PROTAC applications to degrade neo-substrates.

Identifiants

pubmed: 37614621
doi: 10.1101/2023.08.11.553046
pmc: PMC10443223
pii:
doi:

Types de publication

Preprint

Langues

eng

Auteurs

Margot Meyers (M)

Department of Chemistry, University of California, Berkeley, Berkeley, CA 94720 USA.
Novartis-Berkeley Translational Chemical Biology Institute.
Innovative Genomics Institute, Berkeley, CA 94720 USA.

Sabine Cismoski (S)

Department of Chemistry, University of California, Berkeley, Berkeley, CA 94720 USA.
Novartis-Berkeley Translational Chemical Biology Institute.
Innovative Genomics Institute, Berkeley, CA 94720 USA.

Anoohya Panidapu (A)

Department of Chemistry, University of California, Berkeley, Berkeley, CA 94720 USA.
Novartis-Berkeley Translational Chemical Biology Institute.
Innovative Genomics Institute, Berkeley, CA 94720 USA.

Barbara Chie-Leon (B)

Novartis-Berkeley Translational Chemical Biology Institute.
Novartis Institutes for BioMedical Research, Emeryville, CA 94608 USA.

Daniel K Nomura (DK)

Department of Chemistry, University of California, Berkeley, Berkeley, CA 94720 USA.
Novartis-Berkeley Translational Chemical Biology Institute.
Innovative Genomics Institute, Berkeley, CA 94720 USA.
Department of Molecular and Cell Biology, University of California, Berkeley, Berkeley, CA 94720 USA.

Classifications MeSH